Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1984 2
1985 1
1986 1
1988 1
1991 1
1993 1
1994 4
1995 2
1997 4
1998 6
1999 2
2000 1
2002 1
2003 3
2004 9
2005 5
2006 2
2007 3
2008 6
2009 5
2010 6
2011 5
2012 7
2013 3
2014 7
2015 12
2016 13
2017 16
2018 23
2019 17
2020 14
2021 21
2022 17
2023 24
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

228 results

Results by year

Filters applied: . Clear all
Page 1
CTLA-4 tail fusion enhances CAR-T antitumor immunity.
Zhou X, Cao H, Fang SY, Chow RD, Tang K, Majety M, Bai M, Dong MB, Renauer PA, Shang X, Suzuki K, Levchenko A, Chen S. Zhou X, et al. Among authors: fang sy. Nat Immunol. 2023 Sep;24(9):1499-1510. doi: 10.1038/s41590-023-01571-5. Epub 2023 Jul 27. Nat Immunol. 2023. PMID: 37500885
CTLA-4 tail fusion enhances CAR-T anti-tumor immunity.
Zhou X, Cao H, Fang SY, Chow RD, Tang K, Majety M, Bai M, Dong MB, Renauer PA, Shang X, Suzuki K, Levchenko A, Chen S. Zhou X, et al. Among authors: fang sy. bioRxiv [Preprint]. 2023 Mar 15:2023.03.14.532655. doi: 10.1101/2023.03.14.532655. bioRxiv. 2023. PMID: 36993364 Free PMC article. Updated. Preprint.
Applications of CRISPR technology in cellular immunotherapy.
Zhou X, Renauer PA, Zhou L, Fang SY, Chen S. Zhou X, et al. Among authors: fang sy. Immunol Rev. 2023 Nov;320(1):199-216. doi: 10.1111/imr.13241. Epub 2023 Jul 14. Immunol Rev. 2023. PMID: 37449673 Review.
ARX788, a Site-specific Anti-HER2 Antibody-Drug Conjugate, Demonstrates Potent and Selective Activity in HER2-low and T-DM1-resistant Breast and Gastric Cancers.
Skidmore L, Sakamuri S, Knudsen NA, Hewet AG, Milutinovic S, Barkho W, Biroc SL, Kirtley J, Marsden R, Storey K, Lopez I, Yu W, Fang SY, Yao S, Gu Y, Tian F. Skidmore L, et al. Among authors: fang sy. Mol Cancer Ther. 2020 Sep;19(9):1833-1843. doi: 10.1158/1535-7163.MCT-19-1004. Epub 2020 Jul 15. Mol Cancer Ther. 2020. PMID: 32669315
Intra-operative mapping and language protection in glioma.
Weng SM, Fang SY, Li LW, Fan X, Wang YY, Jiang T. Weng SM, et al. Among authors: fang sy. Chin Med J (Engl). 2021 Sep 22;134(20):2398-2402. doi: 10.1097/CM9.0000000000001751. Chin Med J (Engl). 2021. PMID: 34561323 Free PMC article. Review.
Cas12a/Cpf1 knock-in mice enable efficient multiplexed immune cell engineering.
Dong MB, Tang K, Zhou X, Shen J, Chen K, Kim HR, Zhou J, Cao H, Vandenbulcke E, Zhang Y, Chow RD, Du A, Suzuki K, Fang SY, Majety M, Dai X, Chen S. Dong MB, et al. Among authors: fang sy. bioRxiv [Preprint]. 2023 Mar 14:2023.03.14.532657. doi: 10.1101/2023.03.14.532657. bioRxiv. 2023. PMID: 36993642 Free PMC article. Preprint.
228 results